US FDA 510(k) Clearance Issued for SOZO with L-Dex
Filed with ASX · · 1 page · English
Watch Impedimed's latest callImpedimed (ASX:IPD) Q1 2027 Earnings Call · Replay · Oct 29Read the transcript of Impedimed (ASX:IPD) Q1 2027 Earnings CallStory so far
Earlier from Impedimed
- First patient enrolled in SOZO CHF Trial at Scripps Health
- Appendix 4C - Quarter ended 30 June 2017
- IPD Submits FDA 510(k) Application for SOZO for Lymphoedema
- L-Dex Recommended in Clinical Practice Guidelines
- SOZO obtains CE Mark for Heart Failure Patient Monitoring
Later from Impedimed
- Heart Failure 510(k) Application for SOZO Submitted to FDA
- Appendix 4E - year ended 30 June 2017
- New Study Reports Superior Clinical Outcomes Utilising L-Dex
- Shipments of SOZO with L-Dex Commence in the US
- Appendix 4C - Quarter ended 30 September 2017
Follow Impedimed into a list and get an email when it puts out news.
Follow Impedimed